Cargando…

Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings

Purpose  Crizotinib has been one of the standard treatment options for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) based on higher progression-free survival (PFS) and objective response rates in phase III clinical trials. However, real-world data a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Akhil, Noronha, Vanita, Patil, Vijay, Menon, Nandini, Nandhana, Ravindra, Kumar, Amit, Mahajan, Abhishek, Janu, Amit, Kumar, Rajiv, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635771/
https://www.ncbi.nlm.nih.gov/pubmed/37969671
http://dx.doi.org/10.1055/s-0042-1753478
_version_ 1785146360298733568
author Kapoor, Akhil
Noronha, Vanita
Patil, Vijay
Menon, Nandini
Nandhana, Ravindra
Kumar, Amit
Mahajan, Abhishek
Janu, Amit
Kumar, Rajiv
Prabhash, Kumar
author_facet Kapoor, Akhil
Noronha, Vanita
Patil, Vijay
Menon, Nandini
Nandhana, Ravindra
Kumar, Amit
Mahajan, Abhishek
Janu, Amit
Kumar, Rajiv
Prabhash, Kumar
author_sort Kapoor, Akhil
collection PubMed
description Purpose  Crizotinib has been one of the standard treatment options for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) based on higher progression-free survival (PFS) and objective response rates in phase III clinical trials. However, real-world data about the long-term efficacy and toxicity of crizotinib is limited. Methods  A retrospective analysis of all patients with ALK-positive NSCLC, treated with crizotinib between March 2014 and December 2016, was performed. The main outcomes measured were PFS, overall survival (OS), and adverse effects. Results  One hundred and eighty-eight patients treated with crizotinib during this period were included in this study. The median age was 50 years (range: 24–74) with a majority being males (73.2%) and 80.3% with a performance status of 0 to 1. The median duration of follow-up was 49.4 months (range: 3.4–86.3%). The median PFS of crizotinib was 17.3 months (95% confidence interval [CI], 13.0–21.6) and 12.8 months (95% CI, 8.1–17.6) when used in first line or subsequent lines, respectively. The median OS was 38.3 months (95% CI, 28.4–48.2). The patients who received crizotinib in the first line had a median OS of 45.5 months (95% CI, 29.6–61.4) as compared with 29.7 months (95% CI, 22.2–37.2) for those who received in subsequent line (hazard ratio, 0.6, 95% CI, 0.4–0.9, p =0.022). The most common all grade toxicities include transaminitis, anemia, fatigue, and corrected QT prolongation. Conclusion  This real-world study confirms the long-term beneficial effects of crizotinib in ALK rearranged NSCLC with favorable toxicity profile like that of the registration studies, in resource constrained settings.
format Online
Article
Text
id pubmed-10635771
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-106357712023-11-15 Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings Kapoor, Akhil Noronha, Vanita Patil, Vijay Menon, Nandini Nandhana, Ravindra Kumar, Amit Mahajan, Abhishek Janu, Amit Kumar, Rajiv Prabhash, Kumar South Asian J Cancer Purpose  Crizotinib has been one of the standard treatment options for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) based on higher progression-free survival (PFS) and objective response rates in phase III clinical trials. However, real-world data about the long-term efficacy and toxicity of crizotinib is limited. Methods  A retrospective analysis of all patients with ALK-positive NSCLC, treated with crizotinib between March 2014 and December 2016, was performed. The main outcomes measured were PFS, overall survival (OS), and adverse effects. Results  One hundred and eighty-eight patients treated with crizotinib during this period were included in this study. The median age was 50 years (range: 24–74) with a majority being males (73.2%) and 80.3% with a performance status of 0 to 1. The median duration of follow-up was 49.4 months (range: 3.4–86.3%). The median PFS of crizotinib was 17.3 months (95% confidence interval [CI], 13.0–21.6) and 12.8 months (95% CI, 8.1–17.6) when used in first line or subsequent lines, respectively. The median OS was 38.3 months (95% CI, 28.4–48.2). The patients who received crizotinib in the first line had a median OS of 45.5 months (95% CI, 29.6–61.4) as compared with 29.7 months (95% CI, 22.2–37.2) for those who received in subsequent line (hazard ratio, 0.6, 95% CI, 0.4–0.9, p =0.022). The most common all grade toxicities include transaminitis, anemia, fatigue, and corrected QT prolongation. Conclusion  This real-world study confirms the long-term beneficial effects of crizotinib in ALK rearranged NSCLC with favorable toxicity profile like that of the registration studies, in resource constrained settings. Thieme Medical and Scientific Publishers Pvt. Ltd. 2022-09-02 /pmc/articles/PMC10635771/ /pubmed/37969671 http://dx.doi.org/10.1055/s-0042-1753478 Text en MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Kapoor, Akhil
Noronha, Vanita
Patil, Vijay
Menon, Nandini
Nandhana, Ravindra
Kumar, Amit
Mahajan, Abhishek
Janu, Amit
Kumar, Rajiv
Prabhash, Kumar
Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
title Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
title_full Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
title_fullStr Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
title_full_unstemmed Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
title_short Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
title_sort long-term outcomes of crizotinib treated alk-positive lung cancer patients: a retrospective audit of prospective data from resource-constrained settings
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635771/
https://www.ncbi.nlm.nih.gov/pubmed/37969671
http://dx.doi.org/10.1055/s-0042-1753478
work_keys_str_mv AT kapoorakhil longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings
AT noronhavanita longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings
AT patilvijay longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings
AT menonnandini longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings
AT nandhanaravindra longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings
AT kumaramit longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings
AT mahajanabhishek longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings
AT januamit longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings
AT kumarrajiv longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings
AT prabhashkumar longtermoutcomesofcrizotinibtreatedalkpositivelungcancerpatientsaretrospectiveauditofprospectivedatafromresourceconstrainedsettings